FDA expands Mounjaro approval to reduce major cardiovascular risk

What the source reports

The US prescribing information for Mounjaro was updated in August 2026 to add a cardiovascular indication. Tirzepatide is now indicated to reduce the risk of major adverse cardiovascular events—cardiovascular death, non-fatal myocardial infarction or non-fatal stroke—in adults with type 2 diabetes who are at high risk for those events.

Mounjaro was already approved alongside diet and exercise to improve blood-glucose control in adults and children aged 10 years and older with type 2 diabetes. The new decision adds an outcomes-based purpose for eligible adults rather than changing tirzepatide into an emergency treatment for a heart attack or stroke.

Lilly describes Mounjaro as the first dual GIP and GLP-1 receptor agonist with this US cardiovascular-risk indication. That first-in-class point concerns its dual-receptor mechanism; other diabetes medicines, including some GLP-1 receptor agonists, already carry cardiovascular-risk-reduction indications.

Who the new indication covers

The label applies to adults who have type 2 diabetes and are at high cardiovascular risk. It is not a blanket cardiovascular indication for every person taking tirzepatide, and it does not apply to people without type 2 diabetes simply because they have obesity or cardiovascular risk factors.

The pivotal trial enrolled people with type 2 diabetes and established cardiovascular disease. Participants were at least 40 years old and had conditions such as coronary, cerebrovascular or peripheral arterial disease. That trial population is important context when discussing how directly the evidence applies to an individual patient.

The approval is for Mounjaro, the US tirzepatide brand used for type 2 diabetes. It should not be automatically rewritten as a new cardiovascular indication for Zepbound, the tirzepatide brand used for chronic weight management and certain other indications.

What SURPASS-CVOT tested

SURPASS-CVOT was a randomized, double-blind, active-comparator Phase III trial involving 13,299 participants across 30 countries. Participants received once-weekly tirzepatide, up to 15 mg or the maximum tolerated dose, or once-weekly dulaglutide 1.5 mg.

Dulaglutide was not an inactive control. It is a GLP-1 receptor agonist with an established cardiovascular-benefit indication, so the study asked whether tirzepatide could preserve cardiovascular protection relative to an already proven treatment.

The primary outcome was time to the first event in a three-part composite: cardiovascular death, non-fatal heart attack or non-fatal stroke. Median follow-up was about four years, making this the longest and largest completed tirzepatide trial reported to date.

The result: non-inferior, not superior

A primary cardiovascular event occurred in 803 of 6,647 tirzepatide participants, or 12.1%, and 863 of 6,647 dulaglutide participants, or 13.0%. The estimated hazard ratio was 0.92, with a 95.3% confidence interval from 0.83 to 1.01.

That result met the trial’s prespecified test for non-inferiority: tirzepatide was not unacceptably worse than dulaglutide for the composite cardiovascular outcome. The point estimate was 8% lower with tirzepatide, but the confidence interval crossed 1.00 and superiority to dulaglutide was not established.

It is therefore accurate to say that the FDA approved Mounjaro to reduce major cardiovascular risk in the labelled population. It would be inaccurate to say the trial proved Mounjaro prevents more heart attacks, strokes or cardiovascular deaths than Trulicity.

Why the active comparison matters

A placebo-controlled trial can show whether a treatment lowers event risk relative to no active study medicine. SURPASS-CVOT instead compared two active incretin treatments, both given alongside other cardiovascular and diabetes care.

That creates a demanding clinical comparison, but it also changes how the 8% figure should be read. It is a relative comparison with dulaglutide, not an 8% reduction versus placebo and not a promise that an individual’s personal risk will fall by 8%.

Absolute benefit depends on a person’s starting risk, medical history, other treatments and length of follow-up. Composite outcomes also combine different events; the individual heart-attack, stroke and cardiovascular-death estimates were not separately controlled to prove definitive treatment differences.

Safety information still matters

The cardiovascular approval does not remove Mounjaro’s established contraindications, warnings or adverse effects. The current prescribing information retains a boxed warning concerning thyroid C-cell tumours observed in rats and says the medicine is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Warnings also address pancreatitis, hypoglycaemia when used with insulin or an insulin secretagogue, serious hypersensitivity, kidney injury associated with volume depletion, severe gastrointestinal reactions, diabetic-retinopathy complications, gallbladder disease and possible aspiration around anaesthesia or deep sedation.

Nausea, diarrhoea, reduced appetite, vomiting, constipation, indigestion and abdominal pain remain among the commonly reported adverse reactions. A new indication should not prompt anyone to start, stop or change a prescription without discussing their circumstances with a qualified prescriber.

What remains uncertain

The decision does not show that tirzepatide eliminates cardiovascular risk, replaces blood-pressure or cholesterol treatment, or substitutes for smoking cessation and other appropriate risk management. Participants continued broader standard-of-care treatment during the trial.

It also does not establish the same benefit in people without type 2 diabetes, in people at low cardiovascular risk, or for every condition involving the heart. Separate trials and regulatory decisions are needed for different populations and outcomes.

Long-term treatment decisions still require individual assessment of expected benefit, adverse effects, treatment burden, affordability and alternatives. Regulatory approval defines a supported use; it does not decide which medicine is best for every patient.

Bottom line

The FDA’s new indication is a meaningful expansion for Mounjaro. It makes tirzepatide the first dual GIP/GLP-1 receptor agonist approved in the US to reduce cardiovascular death, non-fatal heart attack or non-fatal stroke in high-risk adults with type 2 diabetes.

The strongest interpretation is also the most precise: SURPASS-CVOT showed that tirzepatide maintained cardiovascular protection relative to dulaglutide, an active medicine with proven benefit. The trial’s numerical advantage did not establish superiority, and the approval should not be extended to populations or brand indications that the label does not cover.